Welcome to our dedicated page for Atrium Therapeutics news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Atrium Therapeutics stock.
Avidity Biosciences, Inc. (Nasdaq: RNA) generates news flow centered on its development of Antibody Oligonucleotide Conjugates (AOCs™), a class of RNA therapeutics designed to combine monoclonal antibody specificity with oligonucleotide precision. Company announcements frequently highlight progress across its late-stage neuromuscular pipeline, including programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
News items for RNA often cover clinical trial milestones, such as topline and long-term data from the EXPLORE44® and EXPLORE44-OLE™ studies of delpacibart zotadirsen (del-zota) in DMD44, enrollment and data plans for the HARBOR™ Phase 3 trial of del-desiran in DM1, and development updates for del-brax and the FORTITUDE™ and FORTITUDE-3™ programs in FSHD. Regulatory developments are another key theme, including the FDA’s Breakthrough Therapy designation for del-zota and disclosures about planned Biologics License Application (BLA) submissions.
Investors following Avidity’s news can also expect coverage of financing activities, such as public offerings of common stock, collaboration milestones with partners like Eli Lilly and Company and Bristol Myers Squibb, and updates on the company’s cash position as reported in periodic financial results. Corporate and strategic news includes participation in scientific and investor conferences, as well as detailed announcements about the definitive merger agreement with Novartis AG and the planned separation of early-stage precision cardiology programs into a new company referred to as SpinCo.
In addition, Avidity regularly reports on its engagement with patient and advocacy communities, particularly during National Muscular Dystrophy Awareness Month and events focused on Duchenne muscular dystrophy, myotonic dystrophy, FSHD and rare diseases. For readers tracking RNA, this news page provides a centralized view of clinical, regulatory, financial and transaction-related developments that shape the company’s trajectory.
Avidity Biosciences, Inc. (Nasdaq: RNA) will present at the American Academy of Neurology 2022 Annual Meeting in Seattle, Washington, from April 2-7, 2022. Key oral presentations include findings on Antibody-Oligonucleotide Conjugates (AOCs) for treating Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1. Poster presentations will cover topics such as the patient journey in Facioscapulohumeral Muscular Dystrophy. Avidity aims to advance its clinical programs, with three in development by the end of 2022, focusing on RNA therapeutics to address previously untreatable diseases.
Avidity Biosciences, Inc. (Nasdaq: RNA) announced its participation at the 2022 MDA Clinical & Scientific Conference in Nashville, Tennessee, from March 13-16, 2022. The company will present an oral presentation on DUX4 siRNA Optimization for FSHD Treatment on March 16 and multiple poster presentations discussing real-world data analyses on patients with Facioscapulohumeral Muscular Dystrophy and Myotonic Dystrophy. Avidity is advancing three clinical programs, including its lead candidate AOC 1001 for Myotonic Dystrophy Type 1.
Avidity Biosciences (RNA) reported its fourth quarter and full year 2021 financial results on March 1, 2022, highlighting significant advances in RNA therapeutics. The company ended 2021 with $406 million in cash, bolstered by $175 million raised during the year. Avidity's lead candidate, AOC 1001, is undergoing clinical trials for myotonic dystrophy type 1, with additional programs (AOC 1020 and AOC 1044) expected to enter clinical development in 2022. Collaboration revenue increased to $9.3 million for 2021, up from $6.8 million in 2020.
Summary not available.
Avidity Biosciences, Inc. (Nasdaq: RNA) announced the appointment of Steve Hughes, M.D., as chief medical officer. With over 20 years of experience in clinical development and drug approval, Dr. Hughes aims to advance Avidity's Antibody Oligonucleotide Conjugates (AOCs) platform.
He has contributed to more than 50 clinical trials and played key roles in the approval of rare disease products. Avidity is on track to initiate three clinical programs by the end of 2022, including AOC 1001 for myotonic dystrophy and programs for DMD and FSHD.
Avidity Biosciences (Nasdaq: RNA) announced participation in several major healthcare conferences, showcasing their innovative RNA therapeutic approach through Antibody Oligonucleotide Conjugates (AOCs™). Key events include a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 18, a corporate panel at the Cowen 42nd Annual Health Care Conference on March 7, and another fireside chat at the Needham 21st Annual Healthcare Conference on April 12. Avidity aims to advance their clinical pipeline with AOC 1001 for myotonic dystrophy and additional therapies targeting muscular diseases.
Avidity Biosciences, Inc. (Nasdaq: RNA) announced a live webcast for investors titled "Volume 3: Delivering on AOCs - FSHD" on Dec. 9, 2021, at 11:00 am ET. The company highlighted AOC 1020 as its clinical development candidate for Facioscapulohumeral Muscular Dystrophy (FSHD), which is entering IND-enabling studies. Avidity plans to have three programs in clinical development by the end of 2022, including AOC 1001 for myotonic dystrophy and AOC 1044 for Duchenne Muscular Dystrophy. The MARINA study for DM1 continues with preliminary assessments expected in Q4 2022.
Avidity Biosciences (RNA) reported Q3 2021 financial results, highlighting a significant cash position of $413 million and positive advancements in its AOC pipeline. The initiation of the Phase 1/2 MARINA trial for AOC 1001 marks a transition to a clinical stage company, providing hope for myotonic dystrophy patients. Collaboration revenue increased to $2.2 million from $1.7 million in Q3 2020. However, R&D expenses surged to $24.8 million, up from $9.5 million in the prior year, indicating increased operational costs amid expanding clinical programs.
Avidity Biosciences (Nasdaq: RNA) announced the dosing of the first participants in the Phase 1/2 MARINA trial for its lead product candidate, AOC 1001, marking a significant milestone in RNA therapeutics. The trial targets myotonic dystrophy type 1 (DM1) and is designed to evaluate the safety and tolerability of AOC 1001, which aims to reduce levels of disease-related mRNA DMPK. AOC 1001 has received Orphan Designation from the FDA and EMA, with Fast Track Designation also granted by the FDA for expedited development.
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical firm specializing in RNA therapeutics, will participate in two upcoming conferences. The Credit Suisse 30th Annual Healthcare Conference is scheduled for November 10, 2021, at 2:40 PM ET. Following that, the 4th Annual Evercore ISI HealthCONx Conference will take place on November 30, 2021, at 10:05 AM ET. Live webcasts and archived replays of both events will be available on the company’s website.